Evidence map›Paper›PMID 42181172›Full record

ArticleFrontiers in endocrinology2026

TyHGB and CVD high-risk stratification: nonlinear association and discrimination in the ChinaHEART Luohe study.

Zhiwei Huang, Jirui Cai, Jing Bai, Li Wu, Yabo Huang, Li Guo, Jin Wang, Guirang Zhao, Qiaotao Xie, Haoran Wang

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhiwei Huang *Luohe Central Hospital, Luohe Medical College, Luohe, China.
Jirui Cai *Luohe Central Hospital, Luohe Medical College, Luohe, China.
Jing BaiLuohe Central Hospital, Luohe Medical College, Luohe, China.
Li WuLuohe Central Hospital, Luohe Medical College, Luohe, China.
Yabo HuangLuohe Central Hospital, Luohe Medical College, Luohe, China.
Li GuoLuohe Central Hospital, Luohe Medical College, Luohe, China.
Jin WangLuohe Central Hospital, Luohe Medical College, Luohe, China.
Guirang ZhaoLuohe Center for Disease Control and Prevention, Luohe, China.
Qiaotao XieLuohe Central Hospital, Luohe Medical College, Luohe, China.
Haoran WangLuohe Central Hospital, Luohe Medical College, Luohe, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: TyHGB is a composite metabolic index integrating triglyceride-to-high-density lipoprotein cholesterol ratio, fasting plasma glucose, and body mass index, but its association with World Health Organization (WHO)-defined cardiovascular disease (CVD) high-risk status in community settings remains unclear. Methods: We analyzed 6,755 adults from a community-based ChinaHEART Luohe screening cohort (2021-2022). CVD high-risk was defined as an estimated 10-year WHO CVD risk ≥20%. TyHGB was examined per 1-unit increase and as high versus low using a receiver operating characteristic (ROC)-derived cutoff (Youden index; approximately 7.6). Logistic regression and restricted cubic splines were used to assess associations and potential nonlinearity. Discrimination was evaluated using ROC curves with DeLong's tests, and incremental value beyond conventional risk factors was assessed using integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Results: The prevalence of CVD high-risk was 22%. TyHGB was independently associated with CVD high-risk (fully adjusted OR 1.131 per 1-unit increase), and high TyHGB (≥7.6) was associated with higher odds (OR 1.642). In unadjusted analyses, TyHGB showed higher discrimination than TyG (AUC 0.624 vs 0.585). Adding TyHGB to the base model modestly improved reclassification (IDI 0.003; NRI 0.216). TyHGB was also retained in exploratory machine-learning analyses. Discussion: TyHGB was positively associated with WHO-defined CVD high-risk and provided modest incremental discrimination and reclassification for cross-sectional high-risk classification beyond conventional risk factors, supported by sensitivity analyses. These findings relate to estimated risk status rather than adjudicated incident CVD events.

Indexed as

Blood GlucoseCardiovascular DiseasesCholesterol, HDLTriglyceridesBody Mass IndexChinaFemaleHeart Disease Risk FactorsHumansMaleMiddle AgedPrevalenceRisk AssessmentRisk FactorsBlood GlucoseCholesterol, HDLTriglyceridescardiovascular disease high-riskChinaHEART cohortrisk stratificationtriglyceride-glucose index (TyG)TyHGBWHO CVD risk charts

Identifiers

PMID42181172
PMCPMC13189912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.